HLA class II antibody activation of endothelial cells induces M2 macrophage differentiation in peripheral blood
- PMID: 36611129
- DOI: 10.1007/s10157-022-02307-9
HLA class II antibody activation of endothelial cells induces M2 macrophage differentiation in peripheral blood
Abstract
Background: Donor-specific human leukocyte antigen (HLA) class II antibodies (HLA-II Abs) combined with allogeneic endothelial cells (ECs) mediate high-risk rejection in kidney transplant patients. Macrophage accumulation is a significant histological feature of antibody-mediated rejection (AMR) in kidney transplant patients. Here, we further investigated the effect of HLA-II Abs on macrophage phenotypes to provide theoretical basis for clinical treatment of AMR.
Methods: We prepared an experimental model containing HLA-II Ab-stimulated microvascular ECs and peripheral blood mononuclear cells (PBMCs) co-culture and explored the potential relationship of HLA-II Ab, ECs activation, and macrophage differentiation. Immune phenotype of macrophage subsets was analyzed and quantified by flow cytometry. HLA-II Ab activation of ECs induces M2 macrophage differentiation signal pathways which were investigated by qPCR and western blotting.
Results: The stimulation of ECs by F(ab')2 fragment of HLA-II Abs led to phosphorylation of PI3K, Akt, and mTOR, which mediated IL-10, ICAM-1, VCAM-1 secretion. The enhanced ICAM-1 and IL-10 promoted the migration of PBMCs and their differentiation into CD68+ and CD163+ (M2-type) macrophages, respectively, but not CD86+ macrophages.
Conclusion: These findings revealed the PI3K/Akt/mTOR signal pathways activated by HLA-II Abs in ECs and the immune regulation ability of HLA-II Abs to induce PBMC differentiation.
Keywords: Antibody-mediated rejection; Endothelial cells; HLA-II Abs; M2 macrophage; PBMCs.
© 2022. The Author(s), under exclusive licence to The Japanese Society of Nephrology.
Similar articles
-
HLA Class II-Triggered Signaling Cascades Cause Endothelial Cell Proliferation and Migration: Relevance to Antibody-Mediated Transplant Rejection.J Immunol. 2018 Apr 1;200(7):2372-2390. doi: 10.4049/jimmunol.1701259. Epub 2018 Feb 23. J Immunol. 2018. PMID: 29475988 Free PMC article.
-
Outside-in HLA class I signaling regulates ICAM-1 clustering and endothelial cell-monocyte interactions via mTOR in transplant antibody-mediated rejection.Am J Transplant. 2018 May;18(5):1096-1109. doi: 10.1111/ajt.14544. Epub 2017 Nov 23. Am J Transplant. 2018. PMID: 29045076 Free PMC article.
-
Cross-Talk between HLA Class I and TLR4 Mediates P-Selectin Surface Expression and Monocyte Capture to Human Endothelial Cells.J Immunol. 2022 Oct 1;209(7):1359-1369. doi: 10.4049/jimmunol.2200284. Epub 2022 Sep 2. J Immunol. 2022. PMID: 36165200 Free PMC article.
-
Interplay between immune responses to HLA and non-HLA self-antigens in allograft rejection.Hum Immunol. 2013 Nov;74(11):1478-85. doi: 10.1016/j.humimm.2013.07.002. Epub 2013 Jul 19. Hum Immunol. 2013. PMID: 23876679 Free PMC article. Review.
-
The Transplant Bellwether: Endothelial Cells in Antibody-Mediated Rejection.J Immunol. 2023 Nov 1;211(9):1276-1285. doi: 10.4049/jimmunol.2300363. J Immunol. 2023. PMID: 37844279 Free PMC article. Review.
Cited by
-
Human leukocyte antigen class I antibody-activated endothelium promotes CD206+ M2 macrophage polarization and MMP9 secretion through TLR4 signaling and P-selectin in a model of antibody-mediated rejection and allograft vasculopathy.Am J Transplant. 2024 Mar;24(3):406-418. doi: 10.1016/j.ajt.2023.10.020. Epub 2023 Oct 29. Am J Transplant. 2024. PMID: 38379280 Free PMC article.
References
-
- Zhao L, Hu C, Han F, Cai F, Wang J, Chen J. Preconditioning is an effective strategy for improving the efficiency of mesenchymal stem cells in kidney transplantation. Stem Cell Res Ther. 2020;11(1):197. https://doi.org/10.1186/s13287-020-01721-8 . - DOI - PubMed - PMC
-
- Shaban E, Bayliss G, Malhotra DK, Shemin D, Wang LJ, Gohh R, et al. Targeting regulatory t cells for transplant tolerance: new insights and future perspectives. Kidney Dis (Basel, Switzerland). 2018;4(4):205–13. https://doi.org/10.1159/000490703 . - DOI
-
- Rozentals R, Ziedi L. Antibody-mediated rejection in kidney transplant recipients. Proc Latvian Acad Sci Section B Nat Exact Appl Sci 2013;67(1):2–8.
-
- Wan SS, Ying TD, Wyburn K, Roberts DM, Wyld M, Chadban SJ. The treatment of antibody-mediated rejection in kidney transplantation: an updated systematic review and meta-analysis. Transplantation. 2018;102(4):557–68. https://doi.org/10.1097/tp.0000000000002049 . - DOI - PubMed
-
- Alelign T, Ahmed MM, Bobosha K, Tadesse Y, Howe R, Petros B. Kidney transplantation: the challenge of human leukocyte antigen and its therapeutic strategies. J Immunol Res. 2018;2018:5986740. https://doi.org/10.1155/2018/5986740 . - DOI - PubMed - PMC
MeSH terms
Substances
Grants and funding
- 82070768/National Natural Science Foundation of China (NSFC)
- 2021KW-53/Key Research and Development Program of Shaanxi Province
- xjj2018091/Fundamental Research Funds for the Central Universities
- XJTU1AF-CRF-2019-008/Clinical Research Award of the First Affiliated Hospital of Xi'an Jiaotong University
- 2019JYJH04/Special Supportive Program for Organ Transplantation by COTDF
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous